Sanofi Genzyme forms multiple sclerosis research alliance with Johns Hopkins School of Medicine

To focus on understanding the underlying causes of disease progression in MS

Sanofi Genzyme has announced a research collaboration with the Johns Hopkins School of Medicine in Baltimore, US that will focus on understanding of underlying causes of the progression of multiple sclerosis (MS).

The research group will be guided by a joint committee of representatives from both Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Centre.

'While there are currently no approved treatments for progressive forms of MS, the research landscape is evolving to where we are learning more about the underlying biology of disease progression,' said Michael Panzara, Head of MS, Neurology and Ophthalmology Therapeutic Area, Global Development, Sanofi Genzyme.

'Collaborations like this are important to advancing interventional strategies that slow relentless progression in MS. We are excited about the potential of this collaboration to advance our understanding of disease progression, enabling more rapid development of the next generation of MS therapies.'

Sanofi Genzyme’s MS research pipeline includes collaborations with academic medical centres that explore the pathogenesis of MS and potential novel therapeutics. Initiatives include identifying biomarkers of disease progression and exploring strategies to address neurodegeneration, considered to be a key factor driving disability accumulation in MS.

Companies